Navigation Links
Flexi-Seal(R) Fecal Management System Receives 2008 Critical Care Nurse Advertising Effectiveness Award
Date:7/17/2009

SKILLMAN, N.J., July 17 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today it received first place (Total Recall Category) in the 2008 Critical Care Nurse Advertising Effectiveness Awards for its Flexi-Seal((R) )Fecal Management System (FMS).

The innovative Flexi-Seal((R)) FMS, a temporary containment device for patients with acute fecal incontinence, was designed to safely and effectively divert liquid or semi-liquid fecal matter, help protect patients' wounds from fecal contamination, and reduce the risk of both skin breakdown and spread of infection, such as infection with Clostridium difficile (C. difficile).

"ConvaTec is proud to receive this recognition for Flexi-Seal((R) )FMS from our important customers in critical care nursing," said Michael Steadman, President, ConvaTec USA. "As the leader in helping clinicians manage acute fecal incontinence, we are continuing to respond to customer and patient needs with upgraded and improved features -- an approach that has made Flexi-Seal((R) )FMS the number one brand in the U.S. today."(1) ( )

Critical Care Nurse presented the Award to ConvaTec based on reader responses to a survey comparing 17 advertisements in the publication's October 2008 issue. Survey respondents ranked the Flexi-Seal((R)) FMS advertisement best in the Total Recall Category, with 90 percent responding that they recalled seeing the advertisement, and rated it highly for visual appeal, ease of reading and showing the benefits of the product.

Flexi-Seal((R)) FMS is widely used at over 1,800 intensive care unit hospitals(2) in the United States, and more than 500,000 patients have benefited from the use of Flexi-Seal((R)) FMS.(2) ConvaTec continues to support healthcare professionals with a
'/>"/>

SOURCE ConvaTec
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. New B-SURE Pads Are The Ideal Alternative Product To Use For Mild Fecal Incontinence - Small, Discrete, Absorbent - Order Online At www.birchwoodmedical.com
2. Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers
3. NIH panel seeks to dispel stigma associated with fecal and urinary incontinence
4. Fecal Blood Tests Effective at Spotting Colon Cancer
5. School of Health Management Honors 162 Graduating Students
6. Radiology Benefit Management Could Save Medicare up to $18 Billion Over 10 Years
7. URAC Seeks Public Input on New Uniform External Review Standards for Health Plan and Health Utilization Management Organizations
8. Critical Access Hospital Consolidator Seeks Cost-Management Solutions with Broadlane
9. Digital Storage Solutions Changes Name to Shoreline Records Management, Inc.
10. HealthFitness Makes Compelling Case for Employee Health Management
11. OneTouch(R) Ping(TM) Glucose Management System Approved by Health Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 2Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 3Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 4Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 5Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 6Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 7Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 8Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 9Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:Virus evolution topic of Darwin talk at UH April 2 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 2Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 4Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 5Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 6Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 7Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 8Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 9Health News:National Council on Disability Calls for New Federal Approach to Disability Policy 2
Other Medicine Technology:Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32